Hyperuricemia Medical Services in China

Hyperuricemia is a metabolic disorder characterized by elevated serum uric acid (SUA) levels—defined as >6.8 mg/dL (>405 µmol/L) in men and >5.7 mg/dL (>340 µmol/L) in women—reflecting an imbalance between uric acid production and renal excretion. Uric acid is the end product of purine metabolism in humans; unlike most mammals, humans lack uricase, making them prone to urate accumulation. Pathogenesis involves either overproduction (e.g., due to increased purine synthesis, high dietary purine intake, or enzymatic defects like HGPRT deficiency), underexcretion (accounting for ~90% of cases, often linked to reduced URAT1 or GLUT9 transporter activity in proximal renal tubules), or a combination. Genetic factors—including polymorphisms in SLC2A9, ABCG2, and SLC22A12—significantly influence urate handling. Secondary causes include chronic kidney disease, hypertension, obesity, metabolic syndrome, diuretic use (especially thiazides and loop diuretics), alcohol consumption (particularly beer and spirits), and malignancy-related tumor lysis. Epidemiologically, hyperuricemia affects approximately 14–24% of adults globally, with rising prevalence in China (13.3% overall, up to 21.6% in urban males aged 40–60), driven by aging, dietary Westernization, sedentary lifestyles, and increasing rates of obesity and CKD. Key modifiable risk factors include high-fructose corn syrup intake (e.g., sugary beverages), red meat and seafood consumption, excessive alcohol, insulin resistance, and chronic low-grade inflammation. Non-modifiable risks include male sex, postmenopausal status, family history, and certain ethnic backgrounds (e.g., East Asian and Pacific Islander populations show higher baseline SUA). Although often asymptomatic, persistent hyperuricemia substantially elevates the risk of gout (acute inflammatory arthritis), uric acid nephrolithiasis, chronic kidney disease progression, cardiovascular morbidity (including hypertension, coronary artery disease, and heart failure), and metabolic dysfunction. Quality of life is frequently impaired—even before gout onset—due to anxiety about flare unpredictability, dietary restrictions limiting social engagement, chronic fatigue, sleep disruption from nocturnal flares, and stigma associated with visible tophi or recurrent joint swelling. Untreated, it contributes to long-term disability, work absenteeism, and reduced physical function. Early detection via routine serum uric acid screening—especially in patients with hypertension, diabetes, CKD, or metabolic syndrome—is critical for timely intervention and prevention of irreversible organ damage.

Hyperuricemia is defined as a serum uric acid concentration exceeding 6.8 mg/dL (405 µmol/L)—the physiological saturation threshold at which monosodium urate crystals may precipitate in tissues. It arises from an imbalance between uric acid production and excretion, with approximately 90% of cases attributable to impaired renal urate clearance and 10% to overproduction. Common causes include chronic kidney disease (CKD), particularly stages 2–4, where reduced glomerular filtration rate (GFR) and diminished tubular secretion—mediated by dysfunction of urate transporters such as URAT1 (SLC22A12), ABCG2, and NPT1—lead to retention. Hypertension and heart failure contribute via activation of the renin-angiotensin-aldosterone system (RAAS) and renal vasoconstriction, further compromising urate excretion. Metabolic syndrome components—including insulin resistance, abdominal obesity, dyslipidemia, and hyperglycemia—promote hyperuricemia through multiple mechanisms: hyperinsulinemia inhibits renal urate secretion by downregulating URAT1 and organic anion transporters; adipose tissue releases proinflammatory cytokines (e.g., IL-6, TNF-α) that impair transporter function; and free fatty acids stimulate xanthine oxidase activity. Myeloproliferative and lymphoproliferative disorders (e.g., leukemia, lymphoma, polycythemia vera) cause marked uric acid overproduction due to rapid cellular turnover and purine catabolism, especially during tumor lysis syndrome.

Triggers of acute hyperuricemia exacerbation include dietary surges in purine-rich foods (red meat, organ meats, shellfish, yeast extracts), excessive fructose intake (which depletes intracellular phosphate and accelerates ATP degradation to uric acid), alcohol consumption—particularly beer (high in purines and ethanol, which increases lactate and competes with urate for renal excretion) and spirits—and dehydration, which reduces urinary flow and promotes urate crystallization. Acute illness, surgery, or trauma can induce catabolic stress and tissue breakdown, elevating uric acid levels transiently. Certain medications act as potent triggers: diuretics (especially thiazides and loop diuretics) reduce renal blood flow and inhibit proximal tubular uricosuria; low-dose aspirin (<2 g/day) impairs urate secretion; cyclosporine and tacrolimus diminish glomerular filtration and tubular secretion; and pyrazinamide and ethambutol directly inhibit urate excretion.

Established risk factors encompass male sex (premenopausal women are relatively protected by estrogen-mediated uricosuria), advancing age (declining GFR and altered transporter expression), obesity (BMI ≥30 kg/m² strongly correlates with elevated uric acid), type 2 diabetes mellitus, hypertension, CKD, cardiovascular disease, and nonalcoholic fatty liver disease (NAFLD). Environmental factors include habitual high-purine diets, sedentary lifestyle, chronic dehydration, urban living (associated with processed food consumption and metabolic stress), and exposure to lead—historically linked to chronic interstitial nephritis and reduced urate clearance (saturnine gout). Socioeconomic determinants such as limited access to fresh produce and healthcare also modulate risk.

Genetic factors play a substantial role: genome-wide association studies (GWAS) have identified over 30 loci associated with serum uric acid levels. Key variants include loss-of-function mutations in *ABCG2* (encoding the BCRP transporter), responsible for ~10% of population variance and strongly linked to early-onset gout and renal urate underexcretion; polymorphisms in *SLC2A9* (GLUT9), which encodes a major urate reabsorption transporter in the proximal tubule; and variants in *SLC22A12* (URAT1), *PDZK1*, and *GCKR*. Familial juvenile hyperuricemic nephropathy (FJHN), caused by *UMOD* mutations, leads to defective uromodulin folding, tubulointerstitial fibrosis, and reduced urate excretion. Hereditary xanthinuria (XDH deficiency) and PRPS superactivity (due to *PRPS1* gain-of-function) are rare but definitive overproduction syndromes. Epigenetic regulation—including DNA methylation changes in urate transporter promoters induced by hyperglycemia or oxidative stress—also contributes to interindividual variability. Importantly, hyperuricemia is not merely a biomarker but a pathophysiologically active contributor to endothelial dysfunction, oxidative stress, RAAS activation, and vascular inflammation—underscoring its relevance in endocrinology beyond gout management.

Hyperuricemia is defined as an elevated serum uric acid concentration above the upper limit of normal—typically >6.8 mg/dL (404 µmol/L) in adults—representing the saturation point of uric acid in plasma, beyond which monosodium urate (MSU) crystals may precipitate. It is primarily managed within Endocrinology due to its strong associations with metabolic syndrome, insulin resistance, obesity, dyslipidemia, and hypertension. Importantly, hyperuricemia is often asymptomatic in its early and even prolonged phases; thus, it is frequently identified incidentally during routine biochemical screening rather than through symptom-driven evaluation.

Early symptoms are typically absent or nonspecific. Some individuals may report subtle, non-localized complaints such as mild fatigue, intermittent joint stiffness (particularly in the morning), or vague musculoskeletal discomfort—none of which are diagnostic or reliably attributable to hyperuricemia alone. Subclinical inflammation may be present, reflected by mildly elevated C-reactive protein (CRP) or erythrocyte sedimentation rate (ESR), but these findings lack sensitivity and specificity. Notably, asymptomatic hyperuricemia does not equate to benignity: persistent elevation (>7.0 mg/dL) over years confers increased risk for crystal deposition and end-organ damage, especially in the presence of comorbidities such as chronic kidney disease (CKD) stage ≥2, diabetes mellitus, or cardiovascular disease.

Typical symptoms emerge only upon transition from asymptomatic hyperuricemia to clinical urate crystal–mediated disease. The hallmark presentation is acute gouty arthritis—characterized by sudden, severe, monoarticular (often first metatarsophalangeal joint—"podagra"), exquisitely tender, warm, swollen, and erythematous joint inflammation. Attacks typically peak within 24 hours and last 3–14 days if untreated. Other commonly involved sites include the midfoot, ankle, knee, wrist, and small joints of the hands. Tophaceous gout represents a later-stage manifestation, with visible, firm, chalky subcutaneous deposits (tophi) appearing after ~10 years of uncontrolled hyperuricemia—commonly at the helix of the ear, olecranon bursa, Achilles tendon, or finger extensor surfaces. These tophi may ulcerate, drain white crystalline material, and cause mechanical joint destruction or nerve compression.

Accompanying symptoms reflect systemic metabolic dysregulation and target-organ involvement. Patients frequently exhibit features of metabolic syndrome: central obesity (waist circumference ≥102 cm in men, ≥88 cm in women), fasting hyperglycemia or type 2 diabetes, elevated triglycerides (>150 mg/dL), reduced HDL cholesterol (<40 mg/dL in men, <50 mg/dL in women), and systolic/diastolic hypertension (≥130/85 mmHg). Nonspecific constitutional symptoms may include low-grade fever during acute flares, malaise, and reduced exercise tolerance. Renal involvement may manifest subtly as nocturia, decreased urine output, or frothy urine (suggesting proteinuria); however, overt renal colic or hematuria is uncommon unless nephrolithiasis is present. Uric acid nephrolithiasis occurs in ~10–25% of patients with chronic hyperuricemia and may present with acute flank pain, radiation to the groin, nausea/vomiting, and microscopic or gross hematuria—though stones are radiolucent on standard abdominal X-ray.

Complications arise from chronic crystal deposition and uric acid–induced oxidative stress and inflammation. Chronic tophaceous gout leads to irreversible joint deformity, cartilage erosion, and functional impairment. Urate nephropathy includes both acute uric acid nephropathy (e.g., post-chemotherapy tumor lysis syndrome) and chronic urate nephropathy, characterized by interstitial fibrosis, tubular atrophy, and progressive CKD—often without overt urinary symptoms until late stages. Cardiovascular complications are significant: hyperuricemia independently associates with increased risk of hypertension progression, left ventricular hypertrophy, coronary artery disease, heart failure, and ischemic stroke—likely mediated via endothelial dysfunction, renin-angiotensin system activation, and vascular smooth muscle proliferation. Emerging evidence also links persistent hyperuricemia to nonalcoholic fatty liver disease (NAFLD) progression and cognitive decline, though causality remains under investigation.

Diagnosis relies on quantitative measurement of serum uric acid (SUA) via enzymatic (uricase-based) assay—preferably drawn after an overnight fast, avoiding recent purine-rich meals, alcohol, or diuretic use (which may transiently elevate levels). A single elevated value warrants repeat testing at least one week apart to confirm persistence. Additional essential investigations include renal function assessment (serum creatinine, estimated glomerular filtration rate [eGFR] using CKD-EPI equation), urinalysis (for pH, hematuria, crystalluria), 24-hour urinary uric acid excretion (to classify as overproduction vs. underexcretion), and metabolic panel (glucose, lipid profile, liver enzymes). Imaging modalities include dual-energy CT (DECT), which detects and quantifies MSU crystal deposits with high specificity—even in asymptomatic individuals—and musculoskeletal ultrasound showing the "double contour sign" (hyperechoic band over articular cartilage) and tophus visualization. Plain radiography reveals characteristic "punched-out" lytic bone lesions with overhanging edges in advanced gout but lacks sensitivity for early disease.

Differential diagnosis must exclude secondary causes of hyperuricemia and mimic conditions. Secondary hyperuricemia arises from increased urate production (e.g., myeloproliferative neoplasms, hemolytic anemias, glycogen storage diseases, excessive dietary purine intake, ethanol consumption) or decreased renal excretion (e.g., CKD, heart failure, hypothyroidism, lead poisoning, medications including thiazide and loop diuretics, low-dose aspirin, cyclosporine, pyrazinamide, ethambutol). Pseudogout (calcium pyrophosphate deposition disease) mimics acute gout clinically but demonstrates rhomboid-shaped, positively birefringent crystals on synovial fluid analysis. Septic arthritis presents with similar joint inflammation but features systemic toxicity, markedly elevated WBC and CRP, and positive synovial fluid cultures. Rheumatoid arthritis may show symmetric polyarthritis with morning stiffness >30 minutes, RF/anti-CCP positivity, and erosive changes on imaging—but lacks urate crystals. Other considerations include reactive arthritis, psoriatic arthritis, and cellulitis. Crucially, asymptomatic hyperuricemia itself requires differentiation from transient elevations due to dehydration, acute illness, or medication effects—and should never be diagnosed solely on a single non-fasting value without clinical correlation.

Hyperuricemia—defined as serum uric acid (SUA) concentration exceeding 6.8 mg/dL (405 µmol/L), the physiological saturation threshold for monosodium urate—represents a key metabolic disorder managed primarily within Endocrinology. While often asymptomatic, chronic hyperuricemia predisposes individuals to gouty arthritis, uric acid nephrolithiasis, chronic kidney disease (CKD), hypertension, insulin resistance, and cardiovascular morbidity. Management is stratified according to SUA level, symptom status (asymptomatic vs. gout or nephrolithiasis), comorbidities (e.g., CKD stage, diabetes, heart failure), and urinary uric acid excretion profile (underexcretors vs. overproducers). A comprehensive, evidence-based approach integrates conservative measures, pharmacotherapy, and, rarely, surgical intervention.

Conservative treatment forms the cornerstone of long-term management and must be initiated in all patients, regardless of pharmacologic indication. Dietary modification emphasizes reduction of purine-rich foods—including red meat, organ meats, shellfish, and yeast extracts—while encouraging low-fat dairy, cherries (anthocyanin-mediated xanthine oxidase inhibition), coffee (dose-dependent uricosuric effect), and adequate hydration (>2 L/day to maintain urine output >2 L/day and prevent uric acid crystallization). Alcohol intake—particularly beer (high in purines and ethanol-induced lactic acidosis impairing renal urate excretion) and spirits—must be strictly limited; wine may be consumed in moderation if tolerated. Fructose-sweetened beverages and high-fructose corn syrup are strongly discouraged due to hepatic fructokinase-driven ATP depletion and subsequent uric acid generation. Weight loss—achieved via caloric restriction and aerobic exercise—is recommended for overweight or obese individuals (BMI ≥24 kg/m² in Asian populations), with even 5–10% weight reduction shown to lower SUA by 0.5–1.0 mg/dL. Concurrent management of metabolic comorbidities is essential: optimizing glycemic control in diabetes, using SGLT2 inhibitors (which confer mild uricosuric effects), selecting antihypertensives that do not elevate SUA (e.g., losartan, calcium channel blockers) while avoiding diuretics (especially thiazides and loop diuretics) unless absolutely necessary and closely monitored.

Pharmacologic therapy is indicated when SUA remains ≥9.0 mg/dL despite lifestyle optimization; in patients with recurrent gout flares (≥2/year), tophi, radiographic joint damage, urolithiasis, or CKD stage ≥2 (eGFR <90 mL/min/1.73m²). First-line urate-lowering therapy (ULT) in China and globally is allopurinol, a xanthine oxidase inhibitor (XOI). Initiated at 100 mg/day (50 mg/day in CKD stage 3–4), titrated upward every 2–4 weeks to achieve target SUA <6.0 mg/dL (or <5.0 mg/dL in severe gout), allopurinol is cost-effective, well-studied, and safe with appropriate HLA-B*58:01 screening (mandatory in Han Chinese populations due to 6–8% carrier frequency and markedly increased risk of severe cutaneous adverse reactions including SJS/TEN). Febuxostat, a non-purine XOI, serves as first-line alternative in patients with allopurinol intolerance or contraindication, particularly those with moderate CKD; however, cardiovascular safety requires careful assessment per FDA and EMA guidance. For underexcretors (fractional excretion of uric acid <5.5%), uricosurics—including benzbromarone (highly effective, potent, and widely used in China despite restricted availability elsewhere due to rare hepatotoxicity) and lesinurad (used adjunctively)—are valuable. Benzbromarone is favored in China for its superior efficacy in lowering SUA compared to probenecid and sulfinpyrazone, especially in CKD stages 2–3, though liver enzyme monitoring is mandatory. Topiroxostat, a novel XOI approved in China, offers once-daily dosing and favorable renal safety. Colchicine (0.5–0.6 mg once or twice daily) or low-dose NSAIDs are prescribed prophylactically during ULT initiation for at least 6 months to prevent gout flares triggered by crystal shedding.

Surgical treatment plays an extremely limited role and is reserved exclusively for complications. Tophaceous gout refractory to maximal medical therapy may necessitate surgical tophi debulking—typically for large, ulcerating, infected, or mechanically disabling deposits (e.g., compressing nerves or tendons). Procedures include curettage, excision, or arthroscopic debridement, often combined with joint reconstruction in advanced cases. Uric acid nephrolithiasis unresponsive to medical dissolution (alkalinization + hydration) or causing obstruction/infection may require ureteroscopy with laser lithotripsy or percutaneous nephrolithotomy. Importantly, surgery does not replace ULT; postoperative SUA control remains critical to prevent recurrence.

China offers distinct advantages in hyperuricemia care. First, national clinical guidelines (CSE 2023, CDS 2020) emphasize early, aggressive ULT targeting SUA <5.0 mg/dL in severe gout—more stringent than many Western recommendations—and integrate HLA-B*58:01 pre-screening into routine practice, significantly reducing life-threatening adverse drug reactions. Second, China’s robust domestic pharmaceutical industry ensures broad access to high-quality, affordable generics (allopurinol, benzbromarone) and novel agents (topiroxostat, ulodesine) at substantially lower costs than in high-income countries. Third, integrated traditional Chinese medicine (TCM) modalities—such as acupuncture for pain modulation during flares and standardized herbal formulas (e.g., Si Miao San derivatives) studied for anti-inflammatory and mild uricosuric effects—are increasingly incorporated into multidisciplinary protocols under rigorous quality control. Fourth, China’s tiered healthcare system enables seamless referral from community health centers (for screening, lifestyle counseling, and initial ULT) to tertiary endocrine centers (for complex cases, genetic testing, and biologic therapies under investigation).

Recovery and long-term maintenance hinge on adherence and monitoring. Patients should undergo SUA measurement every 2–4 weeks during ULT titration until target is sustained for ≥3 months, then quarterly thereafter. Renal function (serum creatinine, eGFR, urinalysis), liver enzymes (especially with benzbromarone or febuxostat), and complete blood count must be tracked regularly. Education on flare recognition and self-management—including immediate colchicine use at symptom onset—is vital. Psychological support addresses stigma associated with gout and chronic disease burden. Annual cardiovascular risk assessment (blood pressure, lipid panel, fasting glucose, carotid ultrasound) is recommended given the strong epidemiologic links between hyperuricemia and atherosclerosis. Ultimately, successful management transforms hyperuricemia from a biochemical abnormality into a modifiable cardiovascular-metabolic risk factor—requiring lifelong commitment to integrated, patient-centered care.